High intratumoural 5-hydroxymethylcytosine levels protect against disease relapse in patients with atypical fibroxanthoma and pleomorphic dermal sarcoma.

Hydroxymethylation plays a significant role in cancer development and progression.1-6 We hypothesized that hydroxymethylation markers may have prognostic potential in AFX/PDS (atypical fibroxanthoma/pleomorphic dermal sarcoma) as also observed in other tumours. Moreover, we wanted to find out whether hydroxymethylation markers may aid the differentiation between AFX and PDS.